Tenet Healthcare (THC) Q4 2025 earnings review
High Acuity Masks Soft Volumes; Conifer Deal Clouds 2026
Tenet closed 2025 with a dominant Q4 beat, driving Adjusted EBITDA up 12.9% YoY to $1.18B. The strategy is clear: trade volume for value. While hospital admissions turned negative (-0.7%), revenue per adjusted admission surged 7.5%, proving the 'high acuity' thesis is working. However, the narrative shifts for 2026. The restructuring of the Conifer/CommonSpirit partnership introduces significant accounting noise—removing recurring revenue while injecting lump-sum cash. Underlying leverage is at a multi-year low (2.25x), fueling aggressive buybacks ($1.38B in 2025).
🐂 Bull Case
The Ambulatory (USPI) segment remains the profit engine. Despite lapping tough comps, EBITDA grew 9.4% in Q4 with a massive 40.5% margin. The shift of complex orthopedic and spine cases to ASCs continues to drive rate uplifts (+5.5% revenue per case).
Net leverage dropped to 2.25x (from 2.54x a year ago). With $3.54B in operating cash flow for FY25 and a restructured Conifer deal bringing in $1.9B over three years, Tenet has substantial firepower for M&A and buybacks.
🐻 Bear Case
After three quarters of growth, hospital admissions contracted 0.7% in Q4. While pricing is strong, a sustained volume decline suggests market share loss or demand softness that pricing power cannot offset forever.
The 2026 outlook implies minimal EBITDA growth at the midpoint ($4.63B vs $4.57B in 2025). The removal of Conifer revenues related to CommonSpirit muddies the organic growth picture, potentially spooking investors looking for clean comps.
⚖️ Verdict: 🟢
Bullish. The volume dip is a concern, but the execution on pricing and margins is undeniable. The balance sheet is in its best shape in a decade, and the Conifer deal creates a cash-rich, streamlined operator. The complex 2026 guidance likely hides underlying conservative strength.
Key Themes
The 'Value Over Volume' Pivot
Tenet is effectively culling low-margin volume for high-acuity procedures. In Q4, hospital surgeries were flat (+0.1%) and ER visits declined (-0.3%), yet Adjusted EBITDA soared 16.4%. This is driven by a 7.5% jump in revenue per adjusted admission. The company is extracting significantly more profit from a stagnant asset base.
Conifer Restructuring: Short-Term Pain, Long-Term Cash
The Jan 2026 agreement with CommonSpirit fundamentally changes the Conifer segment. While Tenet receives $1.9B in cash over three years, they lose the recurring revenue from CommonSpirit (formerly 23.8% owner). This creates a 'hole' in 2026 Net Operating Revenue (guidance excludes this revenue), making FY26 look optically slow on growth despite strong underlying cash dynamics.
USPI Pricing Power
USPI (Ambulatory) continues to demonstrate pricing superiority. Revenue per case increased 5.5% YoY in Q4. While case volume growth was modest (+1.6%), the ability to drive rate increases well above inflation preserves the segment's stellar 40%+ EBITDA margins.
Hospital Admissions Contraction
Hospital admissions fell 0.7% YoY in Q4, a sharp reversal from the +5.2% seen in 24Q4 and +1.5% in 25Q3. While 'adjusted' admissions were flat, the core inpatient volume metric turning negative is a red flag. If acuity mix normalizes, this volume hole will damage operating leverage.
Shareholder Returns Accelerating
Tenet is using its deleveraged balance sheet to aggressively return capital. The company bought back $198M in stock in Q4 and $1.386B for the full year 2025. With free cash flow guided to ~$3.1B (midpoint) for 2026, expect buybacks to remain a primary EPS driver.
Other KPIs
Accelerating. Up 12.9% YoY. Margin expanded 70 bps to 21.4%. The company managed to grow EBITDA significantly faster than revenue (+8.9%), demonstrating operational discipline.
Massive improvement from $1.116B in FY24. This was driven by stronger operating performance and presumably better working capital management, despite a slight increase in CapEx ($1.01B vs $931M).
Accelerating. +8.9% YoY growth, the highest rate of the year (compared to -2.7% in Q1, +3.2% in Q2). This reflects the lapping of 2024 divestitures and strong same-store pricing.
Guidance
Stable/Decelerating. The midpoint ($21.9B) implies ~2.7% growth over FY25. Note: This metric excludes revenue from the terminated CommonSpirit contract, masking higher underlying organic growth.
Stable. Midpoint ($4.635B) suggests only +1.5% growth vs FY25 ($4.566B). This reflects the loss of CommonSpirit recurring income offset by organic growth. Margin guidance (20.9% - 21.5%) is roughly flat vs FY25 (21.4%).
Stable. Midpoint ($17.33) is up only ~3% vs FY25 ($16.78). This is conservative given the buyback activity and reduced interest expense potential from deleveraging.
Accelerating. Midpoint is up ~23% vs FY25 ($2.53B). This likely includes cash impacts from the Conifer transaction/tax shield, signaling a massive year for capital deployment potential.
Key Questions
Hospital Volume Reversal
Hospital admissions swung from +1.5% in Q3 to -0.7% in Q4. Is this purely seasonal/flu-related, or are we seeing a structural softening in core inpatient demand?
Conifer Revenue Hole
With the CommonSpirit contract termination revenue excluded from Net Operating Revenues in 2026, can you quantify the specific revenue and EBITDA headwind we are modeling against for organic growth comparison?
Sustainability of Acuity Pricing
Revenue per adjusted admission grew an impressive 7.5%. How much of this is sustainable mix shift versus one-time payer settlements or acuity spikes that might normalize in 2026?